TY - JOUR
T1 - Conjoint Analysis of User Acceptability of Sustained Long-Acting Pre-Exposure Prophylaxis for HIV
AU - Schieffer, Robert J.
AU - Bryndza Tfaily, Ewa
AU - D'aquila, Richard
AU - Greene, George J.
AU - Carballo-Diéguez, Alex
AU - Giguere, Rebecca
AU - Tagliaferri Rael, Christine
AU - Kiser, Patrick F.
AU - Hope, Thomas J.
N1 - Funding Information:
This work was supported by the SLAP-HIV Program (UM1 AI120184 to T.J.H and P.F.K.). Dr. Christine Tagliaferri Rael is supported by a mentored research award from NIMH (K01MH115785: PI: Rael), and a Gray Matters Fellowship from the Columbia University Department of Psychiatry.
Publisher Copyright:
© Copyright 2022, Mary Ann Liebert, Inc., publishers 2022.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Long-acting delivery modalities of HIV pre-exposure prophylaxis (PrEP), such as subdermal implants, are in development. To facilitate end-user uptake and sustained use, it is critical to understand potential consumers' and physician prescribers' preferences about, interest in, and relative importance of different implant features. The ordered identification of these key attributes allows implant developers to incorporate this feedback into product design, which theoretically improves acceptability, feasibility, and user experience with the device. In this study, n = 75 PrEP-prescribing physicians and n = 143 men having sex with men (MSM) at risk for HIV completed web-based surveys that directly compared the importance of eight to nine different implant features, respectively. Conjoint analysis determined the importance of these features, relative to each other. Implants presented in the study were well received, with a majority of physicians and MSM indicating that they were likely to recommend or use them. The implant was perceived as unique, reliable, and convenient, as well as able to deliver better compliance. The attributes most critical to the adoption of the implant among physicians and MSM were (1) the chance of becoming infected with HIV while on implant treatment, (2) the length of protection and size of the implant, and (3) the side effect advantages over current PrEP oral pill treatment. Some concerns about the implant included side effects and the product's safety (among MSM) and the cost or insurance coverage level for the implant (both physicians and MSM). There was also some resistance to the implantation procedure itself.
AB - Long-acting delivery modalities of HIV pre-exposure prophylaxis (PrEP), such as subdermal implants, are in development. To facilitate end-user uptake and sustained use, it is critical to understand potential consumers' and physician prescribers' preferences about, interest in, and relative importance of different implant features. The ordered identification of these key attributes allows implant developers to incorporate this feedback into product design, which theoretically improves acceptability, feasibility, and user experience with the device. In this study, n = 75 PrEP-prescribing physicians and n = 143 men having sex with men (MSM) at risk for HIV completed web-based surveys that directly compared the importance of eight to nine different implant features, respectively. Conjoint analysis determined the importance of these features, relative to each other. Implants presented in the study were well received, with a majority of physicians and MSM indicating that they were likely to recommend or use them. The implant was perceived as unique, reliable, and convenient, as well as able to deliver better compliance. The attributes most critical to the adoption of the implant among physicians and MSM were (1) the chance of becoming infected with HIV while on implant treatment, (2) the length of protection and size of the implant, and (3) the side effect advantages over current PrEP oral pill treatment. Some concerns about the implant included side effects and the product's safety (among MSM) and the cost or insurance coverage level for the implant (both physicians and MSM). There was also some resistance to the implantation procedure itself.
KW - HIV prevention
KW - MSM
KW - PrEP
KW - conjoint analysis
UR - http://www.scopus.com/inward/record.url?scp=85128251152&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128251152&partnerID=8YFLogxK
U2 - 10.1089/aid.2021.0075
DO - 10.1089/aid.2021.0075
M3 - Article
C2 - 34779227
AN - SCOPUS:85128251152
SN - 0889-2229
VL - 38
SP - 336
EP - 345
JO - AIDS research and human retroviruses
JF - AIDS research and human retroviruses
IS - 4
ER -